/SPRINT.ST
SPRINT.ST Stock - Sprint Bioscience AB (publ)
Healthcare|BiotechnologySTO
$1.45+1.40%
+$0.02 (+1.40%) • Dec 23
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.59
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SPRINT.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.43 – $1.46
TARGET (TP)$1.66
STOP LOSS$1.33
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.77
52W High$1.96
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $65.64M | $50.48M | $83,000 | $35.11M | $16.89M |
| Gross Profit | $37.30M | $41.79M | $-60,909,000 | $24.68M | $6.43M |
| Gross Margin | 56.8% | 82.8% | -73384.3% | 70.3% | 38.1% |
| Operating Income | $-19,668,000 | $-845,000 | $-60,909,000 | $-25,466,000 | $-37,675,000 |
| Net Income | $-18,277,000 | $-438,000 | $-60,170,000 | $-25,352,000 | $-46,233,000 |
| Net Margin | -27.8% | -0.9% | -72494.0% | -72.2% | -273.8% |
| EPS | $-0.26 | $-0.01 | $-1.43 | $-0.73 | $-2.23 |
Company Overview
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SPRINT.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.08
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 25, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Nov 25, 2025 | — | $-0.08 | — | — |
Q3 2025 | Aug 27, 2025 | — | $-0.08 | — | — |
Q2 2025 | May 27, 2025 | — | $-0.08 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-0.06 | — | — |
Q4 2024 | Oct 30, 2024 | — | $-0.07 | — | — |
Q3 2024 | Aug 28, 2024 | — | $-0.08 | — | — |
Q2 2024 | May 8, 2024 | — | $-0.04 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.07 | — | — |
Q4 2023 | Oct 25, 2023 | — | $0.41 | — | — |
Q3 2023 | Aug 24, 2023 | — | $-0.17 | — | — |
Q2 2023 | May 10, 2023 | — | $-0.18 | — | — |
Q1 2023 | Feb 15, 2023 | — | $-0.30 | — | — |
Q4 2022 | Oct 26, 2022 | — | $-0.28 | — | — |
Q3 2022 | Aug 24, 2022 | — | $-0.38 | — | — |
Q2 2022 | May 11, 2022 | — | $-0.30 | — | — |
Q1 2022 | Feb 16, 2022 | — | $-0.19 | — | — |
Q4 2021 | Oct 27, 2021 | — | $0.46 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-0.51 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SPRINT.ST
What is SPRINT.ST's current stock price?
Sprint Bioscience AB (publ) (SPRINT.ST) is currently trading at $1.45 per share. The stock has moved +1.40% today.
What is the analyst price target for SPRINT.ST?
No analyst price targets are currently available for this stock.
What sector is Sprint Bioscience AB (publ) in?
Sprint Bioscience AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is SPRINT.ST's market cap?
Sprint Bioscience AB (publ) has a market capitalization of $0.15 billion, making it a small-cap company.
Does SPRINT.ST pay dividends?
No, Sprint Bioscience AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOU.ST
AcouSort AB (publ)
$2.64
Mkt Cap: $0.1B
ACTI.ST
Active Biotech AB (publ)
$0.04
Mkt Cap: $0.1B
ATORX.ST
Alligator Bioscience AB (publ)
$0.34
Mkt Cap: $0.0B
IDLDX.ST
IDL Diagnostics AB (publ)
$0.35
Mkt Cap: $0.1B
LPGO.ST
Lipigon Pharmaceuticals AB (publ)
$0.01
Mkt Cap: $0.0B
ONCOZ.ST
OncoZenge AB (publ)
$6.55
Mkt Cap: $0.1B
PILA.ST
Pila Pharma AB (publ)
$2.20
Mkt Cap: $0.1B
SIMRIS-B.ST
Simris Alg AB (publ)
$0.05
Mkt Cap: $0.0B
SPAGO.ST
Spago Nanomedical AB (publ)
$0.10
Mkt Cap: $0.0B
SPEC.ST
SpectraCure AB (publ)
$0.16
Mkt Cap: $0.1B
Explore stocks similar to SPRINT.ST for comparison